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Alum-adsorbed BBG2Na, a recombinant vaccine derived in part from the respiratory syn-
cytial virus (RSV) subgroup A G protein, induced moderate antibody titers after 1 immu-
nization in 1-week-old mice but conferred complete lung protection upon RSV challenge. The
anti-BBG2Na IgG1-IgG2a neonatal isotype profile was suggestive of dominant Th2 responses
compared with those in adults. Formulation of BBG2Na with a Th1-driving adjuvant effi-
ciently shifted neonatal responses toward a more balanced and adultlike IgG1-IgG2a profile
without compromising its protective efficacy. BBG2Na-induced protective immunity was
maintained even after early life immunization in the presence of high titers of maternal an-
tibodies. Under these conditions, the protective efficacy (86%–100%) reflected the high capacity
of the nonglycosylated G2Na immunogen to escape inhibition by RSV-A–induced maternal
antibodies. Thus, immunization with BBG2Na protected against viral challenge despite ne-
onatal immunologic immaturity and the presence of maternal antibodies, two major obstacles
to neonatal RSV vaccine development.
Respiratory syncytial virus (RSV), a pneumovirus of the Pa-
ramyxoviridae family, is a major respiratory tract pathogen. It
affects humans through repeated infectious episodes. Its clinical
severity is maximal in infancy, in immunosuppressed persons,
and in the elderly [1]. Worldwide, RSV affects most infants
during their ®rst winter season, leading to hospitalization of a
signi®cant (0.5%±2%) fraction [2±5]. Infant protection from
RSV thus represents a major public health issue but is a chal-
lenge that has not been met. Protection in early life requires
the use of vaccines that can rapidly induce protective immune
responses despite the relative immaturity of the immune system
and the persistence of antibodies of maternal origin that can
interfere with infant vaccine responses. Both issues are signif-
icant obstacles to the development of an ef®cient RSV vaccine
[6, 7]. In addition, there is fear that vaccine-induced disease
enhancement at the time of RSV exposure (previously observed
after immunization of seronegative infants with a formalde-
hyde-inactivated viral vaccine [8, 9]) would occur.
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Among the vaccine strategies currently being explored, the
recombinant fusion protein BBG2Na appears to be a promising
RSV vaccine candidate. First, this recombinant protein con-
tains an RSV (Long) G protein fragment (G2Na, aa 130±230),
including a conserved subgroup A±speci®c protective epitope
[10, 11] and a stretch of amino acid residues (aa 164±176) that
are completely conserved in all known human A and B RSV
isolates [12, 13]. Second, this G protein fragment is fused to
the albumin-binding region (BB) of streptococcal protein G,
which is capable of signi®cantly enhancing the in vivo half-life
of fusion partners and thus their exposure to the immune system
[14±17]. This fusion partner also has carrier-related properties
[15] and potentiates the immunogenicity of G2Na [16]. Third,
BBG2Na is produced by prokaryotic expression in Escherichia
coli as a nonglycosylated protein, thereby circumventing the
limitations of the native G protein immunogenicity because of
its heavy glycosylation pattern [17]. The strong immunogenicity
and protective ef®cacy of alum (AlOH)±adsorbed BBG2Na
have been demonstrated against intranasal RSV challenge in
both adult BALB/c mice and cotton rats against both homol-
ogous and heterologous RSV challenge [18]. This new RSV
vaccine candidate is now being evaluated in phase I clinical
studies.
To evaluate whether BBG2Na could induce protection
against RSV lower respiratory tract infections in early life, we
previously used a murine model of neonatal immunization to
evaluate the neonatal immunogenicity of AlOH-adsorbed
BBG2Na. Intraperitoneal (ip) BBG2Na immunization of <1-
week-old BALB/c mice induced signi®cant antibody responses
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[19], but these antibody responses signi®cantly differed from
those in adult mice. First, IgG-speci®c BBG2Na responses to
a single immunization at age 1 week reach antibody titers (∼3.5
log10) that remain 100-fold lower (5.5 log10) than those observed
in response to adult immunization. Second, infant mouse an-
tibody responses to AlOH-BBG2Na also differ qualitatively
from adult responses, being almost exclusively of the IgG1 is-
otype, whereas similar levels of IgG1 and IgG2a antibodies are
generated in adult mice [19]. In view of the quantitative and
qualitative differences in immune responses induced by neo-
natal versus adult immunization, in the present study we eval-
uated whether neonatal BBG2Na immunization via various
immunization routes could protect against an RSV challenge
and whether adultlike, more balanced Th1-Th2 responses to
BBG2Na could be achieved in neonates by changing the ad-
juvant formulation. We also evaluated the protective ef®cacy
of neonatal BBG2Na immunization when given in the presence
of maternal antibodies to RSV-A, whether induced by maternal
exposure to RSV-A or BBG2Na immunization, another critical
issue for vaccine-mediated protection in early life.
Materials and Methods
Mice. Speci®c pathogen-free adult BALB/c inbred mice were
purchased from IFFA-CREDO (L'Arbresle, France), kept under
speci®c pathogen-free conditions at the WHO Center for Neonatal
Vaccinology, and manipulated according to national and European
guidelines. Breeding cages were checked daily for new births, and
the day of birth was recorded as the day the litter was found. Pups
were kept with mothers until weaning at age 4 weeks.
Vaccine antigen, viruses, and cells. The recombinant fusion pro-
tein BBG2Na was expressed and puri®ed in Escherichia coli as
described [18, 20]. Twenty-microgram doses were used per immu-
nization after resuspension either in an isotonic solution containing
AdjuPhos (400 mg of aluminum dose; Superfos BioSector, Vedbaek,
Denmark) or in a formulation containing the CRL8941 adjuvant
in squalene (TiterMax; gift of CytRx, Norcross, GA) according to
the manufacturer's instructions. RSV subgroup A (RSV-A) Long
strain (ATCC VR-26; American Type Culture Collection, Rock-
ville, MD) propagation in HEp-2 cells (ECACC 86030501; Euro-
pean Collection of Animal Cell Cultures, Salisbury, UK), along
with the production of viral and control cell ELISA antigens were
undertaken as described [20].
Immunization and challenge procedures. Litters of 6±8 mice
were immunized by the routes and at the ages indicated in the
®gure legends. Mice were bled at regular intervals to determine
BBG2Na- and RSV-A±speci®c serum antibody titers. When indi-
cated, a booster immunization was given 3 weeks later. For ma-
ternal immunization, 2 doses of BBG2Na (20 mg) or 3 doses of
AlOH-adsorbed RSV-A (Long strain) were given ip at 3-week in-
tervals prior to mating. Offspring were challenged with TCID50
RSV-A by intranasal instillation after being anesthetized with 2.5
mL/kg of a 4/1 mixture (vol/vol) of ketamine (Imalgene 500; RhoÃne
MeÂrieux, Lyon, France) and xylazine (Rompun 2%; Bayer, Pu-
teaux, France). Mice were sacri®ced 5 days after challenge, coin-
cident with previously characterized peak RSV lung titers [21].
Quantification of vaccine- and RSV-specific antibodies.
BBG2Na- and RSV-A±speci®c IgG and subclass antibodies were
determined by ELISA. In brief, ¯at-bottomed wells of microtiter
plates (MaxiSorp; Nunc, Roskilde, Denmark) were coated over-
night at 47C with 50 mL of a 4 mg/mL solution of BBG2Na in PBS
or at 377C and low humidity with 50 mL of RSV-A or HEp-2 cell
protein preparations previously calibrated according to their reac-
tivity with relevant reference sera. After a wash with PBS-0.05%
Tween 20 and blocking with 4% milk solids, serial dilution of sera
were added and incubated for 2 h at room temperature. The rel-
evant isotype-speci®c peroxidase-conjugated goat or rabbit anti-
mouse (Zymed Laboratories, South San Francisco) was added for
2 h at 377C prior to incubation with substrate. Optical density
results were expressed as antibody titers by reference to a titered
reference serum representing a pool of sera from immunized adult
mice. As the virus stocks contained cellular antigen, anti±RSV-
A±speci®c antibody titers of mice infected with RSV-A were cal-
culated by subtracting anti±HEp-2 optical density values from
those of anti±RSV-A.
Animal sample preparation and virus titration. Animals were
anesthetized as described above and exsanguinated by cardiac
puncture. Lung removal, lung homogenate preparation, and virus
titration in the homogenates were done as previously described
[18]. The limit of detection for lung tissues was log10 1.45 TCID50/
g lung, except where insuf®cient lung homogenate was available.
When no virus was detected, actual detection limits were used for
statistical analyses. Thus, standard deviations 10 were occasionally
recorded for lung titers of some virus-free animal groups. Lungs
were considered protected when virus titers were reduced by >2
log10 relative to control mice.
Statistical analysis. Unless otherwise indicated, signi®cance
analyses of antibody levels from various groups of mice were done
by Wilcoxon rank test. For statistical analyses of viral titers, we
used t or Kolmogorov-Smirnov (for low sample numbers) tests and
x2 tests (Statigraphic software program; Manugistics, Rockville,
MD). was considered insigni®cant.P 1 .05
Results
Protective efficacy of neonatal immunization with BBG2Na.
To assess whether BBG2Na immunization could induce pro-
tective immune responses in the ®rst week of life, BALB/c pups
were immunized at age 1 week with a single dose of BBG2Na
(20 mg) adsorbed to aluminum phosphate (AlPO4), the adjuvant
formulation selected for clinical trials. Immunization was done
either ip or intramuscularly (im), routes likely to be adopted
in humans. Age-matched control pups were given PBS ip. Mice
were bled 4 weeks after immunization to determine BBG2Na-
and RSV-A±speci®c antibody titers. Signi®cant IgG antibody
responses were elicited by a single neonatal immunization in
22 mice (®gure 1A); no vaccine-speci®c antibodies were detected
in 1 mouse. This mouse was considered inef®ciently immunized
and excluded from further analyses. Under the conditions de-
scribed, vaccine-speci®c and RSV-A±speci®c IgG antibody re-
sponses were similar regardless of immunization route. All PBS-
injected controls remained seronegative (®gure 1A). However,
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Figure 1. Immunogenicity and protective ef®cacy of neonatal
BBG2Na immunization. Mice were immunized intraperitoneally (ip)
or intramuscularly (im) at age 1 week with 20 mg of BBG2Na resus-
pended in AlPO4. Age-matched control pups received PBS ip. A,
BBG2Na- and RSV-A±speci®c antibodies were measured by ELISA 4
weeks after immunization and expressed as antibody titers by reference
to titered reference serum. B, Mice were sacri®ced 5 days after intra-
nasal RSV-A challenge for virus titration in lung homogenates as de-
scribed in Materials and Methods. Results are expressed as log10
TCID50/g lung tissue.
Figure 2. Isotype distribution of antibodies after neonatal BBG2Na
immunization. Mice were immunized at age 1 week or as adults with
20 mg of BBG2Na resuspended in AlPO4 and given intraperitoneally
(ip), intramuscularly (im), or subcutaneously (sc) or with the same dose
of BBG2Na resuspended in TiterMax (TMax). IgG1 and IgG2a
BBG2Na-speci®c antibodies were measured by ELISA 4 weeks after
immunization and expressed as antibody titers by reference to titered
reference serum.
as previously observed in mice immunized ip with AlOH-
BBG2Na, BBG2Na antibody responses remained signi®cantly
lower than those elicited in 28 adult mice whose antibody titers
were already 10-fold higher ( log10) 2 weeks after ip4.98 5 0.33
immunization.
Immune and control litters were simultaneously challenged
intranasally 4 weeks after immunization (i.e., at age 5 weeks).
All animals remained asymptomatic and were sacri®ced 5 days
later to measure RSV-A lung titers. High lung virus titers were
measured in all PBS control pups (®gure 1B). In contrast, lung
protection was observed in all 20 pups immunized ip or im with
BBG2Na; 19 of 20 pups were virus-free (the remaining pup
was positive for virus at the limit of detection of the assay).
No difference in protective ef®cacy was observed with ip or im
immunization.
Influence of adjuvant formulation on immunogenicity and pro-
tective efficacy of neonatal BBG2Na immunization. We did
comparative analyses of the IgG1 and IgG2a subclass distri-
bution of vaccine-speci®c antibodies (selected as indirect mark-
ers of Th1-Th2 response type) 4 weeks after immunization.
After neonatal AlPO4-BBG2Na immunization, vaccine anti-
bodies were almost exclusively among the IgG1 and only rarely
(4/23 weakly positive mice) among the IgG2a isotypes (®gure
2). This was not signi®cantly in¯uenced by the immunization
route and contrasted with the presence of IgG2a antibodies in
all 28 mice immunized as adults (®gure 2).
We thus asked whether a change of adjuvant formulation
(selecting a product known to induce strong Th1 responses in
either adult or young mice [22] in contrast to aluminum salts,
which preferentially support Th2 responses both in mice and
humans [23]) would affect immunogenicity and protective ef-
®cacy of neonatal BBG2Na immunization. We immunized 1-
week-old pups with BBG2Na resuspended in TiterMax, an ad-
juvant formulation composed of block copolymers in a
water-in-oil emulsion, prior to subcutaneous (sc) immunization.
Control pups were given AlPO4-BBG2Na sc. Following sc
AlPO4-BBG2Na immunization, vaccine antibodies were again
exclusively of the IgG1 isotype (®gure 2). In contrast, in pups
immunized in the presence of TiterMax, BBG2Na-speci®c an-
tibodies were similarly distributed among the IgG1 and IgG2a
isotypes, suggesting successful induction of balanced Th1-Th2
responses (®gure 2).
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Figure 3. In¯uence of adjuvant on immunogenicity and protective
ef®cacy of neonatal BBG2Na immunization. Mice were immunized
subcutaneously (sc) at age 1 week with 20 mg of BBG2Na resuspended
in AlPO4 or in TiterMax (Tmax) as indicated. A, Age-matched control
pups received PBS sc; BBG2Na- and RSV-A±speci®c antibodies were
measured by ELISA 4 weeks after immunization and expressed as
antibody titers by reference to titered reference serum. B, Mice were
sacri®ced 5 days after intranasal RSV-A challenge, and virus titers in
lung homogenates were determined as described in Materials and
Methods. Results are expressed as log10 TCID50/g lung tissue.
Figure 4. In¯uence of maternal antibodies on immune responses to
BBG2Na. Pups born to RSV-A± or BBG2Na-immunized mothers (A
and B, respectively) were immunized intramuscularly at age 1 week
with AlPO4-BBG2Na and boosted 4 weeks later; controls received PBS.
Age-matched pups of control seronegative mothers were immunized as
controls. Mice were bled monthly for determination of RSV-A (A) and
BBG2Na (B) antibodies by ELISA. Results (representative of 2±4 lit-
ters) are expressed as antibody titers by reference to titered reference
serum.
To assess whether this change of immunogenicity would af-
fect responses to intranasal RSV challenge, litters immunized
sc with BBG2Na-AlOH (2 litters) or BBG2Na-TiterMax (2
litters) and PBS-immunized controls were challenged simulta-
neously 4 weeks after immunization. All mice remained asymp-
tomatic. In correlation with induction of vaccine-speci®c and
RSV-A±speci®c antibodies (®gure 3A), high lung virus titers
were measured in all seronegative nonimmune control pups
(®gure 3B). In contrast, lung protection was again observed in
pups immunized with BBG2Na, regardless of the adjuvant for-
mulation used for neonatal immunization: all 28 challenged
pups were protected, and 27 of 28 remained virus-free.
Influence of maternal antibodies on protective efficacy of neo-
natal BBG2Na immunization. To assess whether high levels
of RSV-A antibodies of maternal origin would in¯uence
BBG2Na vaccine±induced protection, BALB/c female mice
were immunized either 3 times with RSV-A or twice with
BBG2Na prior to mating to induce high levels (5±6 log10) of
RSV-A antibodies. Pups born to immune or control nonim-
mune mothers were immunized im with AlPO4-BBG2Na at age
1 week and boosted 3 weeks later, following a protocol pre-
viously shown to induce long-lasting vaccine responses in pups
of nonimmune mothers (not shown). Control pups born to
immune mothers received only PBS to allow evaluation of the
kinetics of maternal antibody decline. All mice were bled at
regular intervals for determination of RSV-A±BBG2Na
antibodies.
In pups of RSV-A±immunized mothers (®gure 4A), RSV-A
antibodies of maternal origin were initially very high (5.5±6.0
log10). As expected, they steadily declined over 16 weeks in
nonimmunized control pups. In contrast, in pups of RSV-
A±immunized mothers that were immunized with BBG2Na in
early life, RSV-A antibodies initially declined over 8 weeks but
remained elevated when they reached the antibody titer (∼4
log10) that corresponded to normal antibody responses induced
in pups of nonimmune mothers (®gure 4A). Similar patterns
were observed in experiments with pups of BBG2Na-immu-
nized mothers (®gure 4B). Vaccine antibodies of maternal origin
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Table 1. In¯uence of maternal antibodies on protective ef®cacy of
neonatal BBG2Na immunization.
Immunogen RSV-A titer (mean 5 SD) No. virus
free/no.
challengedTo mothers To offspring Antibodya Lungb
Part A
Experiment 1
a. RSV-A PBS !1.7 5 0.0 4.45 5 0.29 0/4
b. RSV-A BBG2Na 3.8 5 0.7 1.45 5 0.0c 4/4
c. None BBG2Na 3.1 5 1.0 1.56 5 0.3c 5/6
Experiment 2
a. RSV-A PBS !1.7 5 0.0 4.40 5 0.33 0/5
b. RSV-A BBG2Na 4.0 5 0.9 1.45 5 0.0d 7/7
c. None BBG2Na 3.9 5 0.5 1.47 5 0.0d 5/5
Part B
Experiment 3
a. BBG2Na PBS !1.7 5 0.0 3.77 5 1.18 0/7
b. BBG2Na BBG2Na 3.2 5 0.7 1.53 5 0.2d 5/6
c. BBG2Na BBG2Na 3.6 5 0.3 1.45 5 0.0d 7/7
d. None BBG2Na 3.5 5 0.3 1.50 5 0.1d 4/5
e. None BBG2Na 4.0 5 0.5 1.45 5 0.0c 4/4
Experiment 4
a. BBG2Na PBS !1.7 5 0.0 4.45 5 0.27 0/6
b. BBG2Na BBG2Na 3.2 5 0.9 2.01 5 0.95d 3/8
c. BBG2Na BBG2Na 3.9 5 0.6 1.92 5 1.0d 5/8
d. None BBG2Na 4.5 5 0.5 1.45 5 0.0d 5/7
NOTE. Offspring of immune and control mothers, previously injected at age
1 week with BBG2Na or PBS and boosted 3 weeks later, were bled for deter-
mination of RSV-A antibody titers. Litters were challenged through 4 independent
experiments after disappearance of maternal antibodies in unimmunized control
pups (116 weeks), which were challenged simultaneously. Signi®cance was de-
termined for each litter (a±e) within each experimental group (experiments 1±4)
relative to nonimmunized controls from immune mothers (litters a).
a ELISA titer, log10.
b RSV-A titer, log10 TCID50/g lung.
c (nonparametric test; Kolmogorov-Smirov test because of low sampleP ! .05
numbers).
d (t test using null hypothesis).P ! .002
slowly declined from 5.5 log10 to undetectable levels in non-
immunized control pups of immune mothers; they remained at
high levels in BBG2Na-immunized pups of immune mothers.
Although BBG2Na antibody responses occasionally and tran-
siently reached higher titers in control pups of nonimmune
mothers, they stabilized at the same antibody level as that in-
duced in pups of immune mothers.
To allow evaluation of the protection induced by neonatal
immunization without any interference from residual antibodies
of maternal origin, which can confer passive protection [19],
intranasal RSV-A challenge was scheduled only after disap-
pearance of maternal antibodies in nonimmunized pups of
RSV-A±BBG2Na immune mothers, that is, at 116±20 weeks.
Challenge was done in 4 successive experiments: each included
immunized and control pups of immune mothers and immu-
nized pups of control mothers. For offspring of RSV-A±
immunized mothers (table 1, part A), high RSV-A virus titers
were present after challenge in lungs of nonimmunized pups of
immune mothers, con®rming that antibodies of maternal origin
had fallen below protective levels. In contrast, all 22 BBG2Na-
immunized pups were protected, whether immunization was
done in the absence or presence of high RSV-A maternal an-
tibodies. Twenty-one (96%) of these 22 immunized pups were
virus-free when tested 5 days after challenge.
In the second series of experiments, we evaluated protective
ef®cacy in pups of BBG2Na-immune or control mothers (table
1, part B). High RSV-A virus titers were present in the lungs
of 12 of 13 nonimmunized pups of BBG2Na-immune mothers.
Among pups of control seronegative mothers, 16 of 16 chal-
lenged pups were protected from RSV-A by BBG2Na immu-
nization, while 13 (81%) of 16 were virus-free. For pups im-
munized in the presence of high levels of BBG2Na maternal
antibodies, 25 (86%) of 29 were protected from intranasal RSV-
A challenge, while 20 (69%) of 29 were virus-free. Although
the protective ef®cacy of BBG2Na immunization in pups of
BBG2Na mothers (table 1, part B) was not signi®cantly dif-
ferent ( ) from that in pups of RSV-A±exposed mothersP 5 .1
(table 1, part A), complete protection (i.e., no detectable virus
5 days after challenge) signi®cantly differed between groups
(96% vs. 69%, ). RSV-A antibodies present immediatelyP 5 .02
before viral challenge in the 4 unprotected pups born to
BBG2Na-immune mothers were low (2.1 and 2.4 log10) in 2
unprotected pups but reached signi®cant levels (3.2 and 4.8
log10) in the remaining 2 mice.
Discussion
The immaturity of the neonatal immune system and the pres-
ence of high titers of antibodies of maternal origin are two
major obstacles to the development of vaccine-mediated pro-
tection against RSV lower respiratory tract infections [6, 7].
The immaturity of the immune system affects both innate and
speci®c immune responses required for viral neutralization and
clearance through mechanisms as yet only partly understood
(reviewed in [24]). Among them, limitation of antigen-speci®c
antibody responses is an important parameter. It affects infant
responses to RSV antigens and is responsible for limited se-
rologic responses of infants !6±9 months after RSV infection
[7, 25] or immunization with RSV vaccine candidates [6]. Lim-
itation of early life antibody responses to vaccines is also ob-
served in murine models of neonatal immunization [26], which
thus appear to be of interest for preclinical evaluation of vaccine
antigens or formulations early in life. Accordingly, BBG2Na
vaccine responses triggered in the ®rst weeks of life were slower
and 100-fold weaker than those induced in adult controls [19].
We show here that a single immunization with BBG2Na
(whether ip, im, or sc) conferred complete protection against
intranasal RSV challenge in mice, even when immunization was
done at a stage of immune immaturity (i.e., age 1 week) con-
sidered to best approximate the immune capacity of human
newborns (unpublished observations). Should the characteris-
tics of BBG2Na allow the induction of equally strong protective
immune responses in humans, which is currently being evalu-
ated by clinical testing, its capacity to induce protective immune
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responses early in life would meet an important requirement
for prevention of severe RSV disease in infants.
Another parameter of the immaturity of early life immune
responses is recognized in murine models as the preferential
polarization of neonatal vaccine responses toward the Th2 phe-
notype, even in response to vaccine antigen formulations or
delivery systems that induce balanced Th1-Th2 responses in
adults [26±28]. This is currently thought to re¯ect the higher
activation requirements of neonatal versus adult antigen pre-
senting cells (APCs), which result in suboptimal APC±T cell
interactions, rather than re¯ecting intrinsic limitations of ne-
onatal T cells (reviewed in [24]). The bias of neonatal vaccine
responses to ALOH-BBG2Na ip immunization [19] was also
observed here by use of AlPO4-adsorbed BBG2Na, whether
administered ip, im, or sc. Of importance, however, this Th2
polarization of neonatal responses did not affect BBG2Na pro-
tective ef®cacy, which is as strong after a single vaccine dose
in early life as in adult mice [18].
Priming for preferential Th2 vaccine responses upon neonatal
immunization also raises the concern of immunopotentiation
of RSV disease at the time of subsequent natural viral infection.
Components of the phenomenon observed in seronegative in-
fants during the clinical trials of FI-RSV [8, 9] were similarly
inducible in BALB/c mice and correlated with an intensi®ed
production of Th2-derived cytokines [29]. Furthermore, exper-
iments that used vaccinia virus recombinant vectors [30±32] or
puri®ed protein preparations revealed that native G protein
strongly induced Th2-type cytokine synthesis and lung im-
munopathology, even when used with the Th1-driving QS-21
adjuvant [32]. In addition, aluminum salts (the single adjuvants
currently authorized for infant immunization) further contrib-
ute to a preferential Th2 polarization of vaccine responses [23].
Thus, it was important to ask whether a change in the adjuvant
formulation could induce adult-like balanced Th1-Th2 re-
sponses to BBG2Na in early life. A change in the adjuvant
formulation of BBG2Na was suf®cient to restore the balanced
IgG1-IgG2a antibody responses observed in adult mice, and
this change of immunogenicity did not affect the protective
capacity of neonatal immunization. Thus, a Th2 polarization
of responses cannot be considered as an intrinsic limitation of
all G protein±derived vaccines [30±32], and BBG2Na could be
used with Th1-driving adjuvants if required for safety reasons.
However, parallel studies recently showed that even AlOH-ad-
sorbed BBG2Na did not prime for deleterious Th2-type anti-
RSV immunopathologic responses at the time of RSV exposure
in an adult BALB/c mouse model [33, 34]. If this immuno-
potentiation model can be adapted to the neonatal period as
currently evaluated, it would enable further preclinical evalu-
ation of the safety of neonatal BBG2Na immunization.
Because of the ubiquitous nature of RSV and the frequency
of reinfections in adults, RSV antibodies of maternal origin are
present at birth at low, moderate, or sometimes even high titers
[25]. Passively transferred antibodies can confer protection from
RSV disease both in humans [35] and in murine models of
maternal immunization with BBG2Na [19]. However, the pro-
tection conferred by maternal antibodies is transient, and pro-
longed protection requires associated infant immunization. Un-
fortunately, maternal antibodies may interfere with neonatal
vaccine responses. This inhibition of antibody responses affects
infant responses to RSV antigens [6, 7], as shown in rodent
models that used either live RSV-A [36, 37], F- and G-express-
ing recombinant vaccinia viruses [38], or puri®ed F and G gly-
coproteins [39]. In striking contrast, even high titers of RSV-
A maternal antibodies (5 log10) did not inhibit induction of
murine antibody responses to BBG2Na [19]. Accordingly, we
show here that the protective capacity of neonatal BBG2Na
immunization reached 100% in the presence of maternal anti-
bodies induced by repeated exposure to RSV-A: 96% of pups
were free of virus 5 days after challenge. We previously showed
the capacity of BBG2Na immunization to induce strong an-
tibody responses even in the presence of passively transferred
maternal antibodies induced by intranasal RSV infection [19].
Intraperitoneal use of live RSV in alum induced antibody titers
that were higher (5.5±6.0 log10) than those induced after repeat
intranasal infection and readily transferred to the offspring,
thereby resulting in higher levels of maternal anti±RSV-A an-
tibodies in the neonates. To our knowledge, this is the ®rst
description of vaccine-induced protection from RSV challenge
observed after early life immunization in the presence of high
levels of RSV-A maternal antibodies.
Pups of BBG2Na-immunized mothers raised similarly high
antibody responses to BBG2Na, and protective ef®cacy of neo-
natal BBG2Na immunization was high (86%). However, com-
plete protection (no detectable virus 5 days after challenge) was
observed signi®cantly less often than in pups of RSV-A±
exposed mothers (69% vs. 100%). This difference in BBG2Na
neonatal protective ef®cacy following RSV-A or BBG2Na ma-
ternal immunization is unlikely to re¯ect differences in induc-
tion of T cell vaccine responses, since maternal antibodies were
shown in parallel immunization models not to alter neonatal
T cell responses to vaccines [40]. Differences in maternal an-
tibody titers present in pups at the time of immunization cannot
account for this difference in protective ef®cacy. A more at-
tractive hypothesis is that the capacity of BBG2Na to largely
escape inhibition by RSV-A maternal antibodies re¯ects an im-
munogenicity of the nonglycosylated G2Na fragment that is
partly different from that of the native RSV G protein. Since
inhibition of infant antibody responses by maternal antibodies
is epitope-speci®c, their in¯uence is indeed greater when the
same vaccine antigen is used in both mothers and infants [41].
We therefore suggest that binding of BBG2Na-induced mater-
nal antibodies to certain speci®c protective epitopes of BBG2Na
could inhibit the induction of infant responses to such epitopes,
occasionally reducing protective ef®cacy. Given the interest in
maternal immunization to prevent early RSV infection, analysis
of the hierarchy of epitope recognition following neonatal
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BBG2Na immunization of pups of control, RSV-A± or
BBG2Na-immunized mothers by use of peptide-based ELISA
and pepscan analyses is ongoing. Should a modi®cation of ep-
itope recognition be identi®ed following immunization in the
presence of high levels of maternal antibodies to BBG2Na, it
could contribute to the identi®cation of protective B cell epi-
topes in BBG2Na.
In conclusion, this study provides a promising preclinical
evaluation of the capacity of BBG2Na immunization to induce
protection from RSV lower respiratory disease in early life. Its
unique features allow BBG2Na to induce protective immune
responses even after a single immunization given at an early
stage of immune maturation, whether adsorbed to aluminum
salts or given with Th1-driving adjuvant formulations. It also
suggests that the distinct immunogenicity of BBG2Na could
allow induction of protective vaccine responses early, even in
presence of high titers of RSV-A maternal antibodies. These
distinct properties make BBG2Na an interesting RSV vaccine
candidate.
Acknowledgments
We thank Dominique Cyblat and Francis Derouet for excellent tech-
nical assistance and the Centre de DeÂveloppement Pierre Fabre for
providing the BBG2Na formulations.
References
1. Collins, PL, McIntosh K, Chanock RM. Respiratory syncytial virus. In:
Fields BN, Knipe DM, Howley PM, eds. Fields virology. Philadelphia:
Lippincott-Raven, 1996:1313±51.
2. Parrott RH, Kim HW, Arrobio JO, et al. Epidemiology of respiratory syn-
cytial virus infection in Washington, DC. II. Infection and disease with
respect to age, immunologic status, race and sex. Am J Epidemiol 1973;98:
289±300.
3. Martin AJ, Gardner PS, McQuillin J. Epidemiology of respiratory viral in-
fection among pediatric inpatients over a six year period in northeast
England. Lancet 1978;2:1035±8.
4. Glezen WP, Paredes A, Allison JE, et al. Risk of respiratory syncytial virus
infection for infants from low-income families in relationship to age, sex,
ethnic group and maternal antibody level. J Pediatr 1981;98:708±15.
5. Green M, Brayer AF, Schenkman KA, Wald ER. Duration of hospitalization
in previously well infants with respiratory syncytial virus infection. Pediatr
Infect Dis J 1989;8:601±5.
6. Belshe RB, van Voris LP, Mufson MA. Parenteral administration of live
respiratory syncytial virus vaccine: results of a ®eld trial. J Infect Dis
1982;145:311±9.
7. Murphy BR, Alling DW, Snyder MH, et al. Effect of age and preexisting
antibody on serum antibody response of infants and children to the F
and G glycoproteins during respiratory syncytial virus infection. J Clin
Microbiol 1986;24:894±8.
8. Chin J, Magof®n RL, Shearer LA, Schieble JH, Lennette EH. Field evalu-
ation of a respiratory syncytial virus vaccine and a trivalent parain¯uenza
virus vaccine in a pediatric population. Am J Epidemiol 1969;89:449±63.
9. Kim HW, Leikin SL, Arrobio JO, Brandt CD, Chanock RM, Parrott RH.
Cell-mediated immunity to RSV induced by inactivated vaccine or by
infection. Pediatr Res 1976;10:75±8.
10. AÊ kerlind-Stopner B, Utter G, Mufson MA, Orvell C, Lerner RA, Norrby
E. A subgroup-speci®c antigenic site in the G protein of respiratory syn-
cytial virus forms a disul®de-bonded loop. J Virol 1990;64:5143±8.
11. Trudel M, Nadon F, Seguin C, Binz H. Protection of BALB/c mice from
respiratory syncytial virus infection by immunization with a synthetic
peptide derived from the G glycoprotein. Virology 1991;185:749±57.
12. Garcia O, Martin M, Dopazo J, et al. Evolutionary pattern of human res-
piratory syncytial virus (subgroup A): cocirculating lineages and corre-
lation of genetic and antigenic changes in the G glycoprotein. J Virol
1994;68:5448±59.
13. Makrides SC, Nygren PAÊ , Andrews B, et al. Extended in vivo half-life of
human soluble complement receptor type 1 fused to a serum albumin-
binding receptor. J Pharmacol Exp Ther 1996;277:534±42.
14. Sullender WM, Mufson MA, Anderson LJ, Wertz GW. Genetic diversity of
the attachment protein of subgroup B respiratory syncytial viruses. J Virol
1991;65:5425±34.
15. SjoÈ lander A, Nygren PAÊ , StaÊhl S, et al. The serum albumin-binding region
of streptococcal protein G: a bacterial fusion partner with carrier-related
properties. J Immunol Methods 1997;201:115±23.
16. Libon C, Corvaia N, Haeuw JF, et al. The serum albumin-binding region of
streptococcal protein G (BB) potentiates the immunogenicity of the G130-
230 RSV-A protein. Vaccine 1999;17:406±14.
17. Wagner DK, Muelenaer P, Henderson FW, et al. Serum immunoglobulin G
antibody subclass response to respiratory syncytial virus F and G gly-
coproteins after ®rst, second, and third infections. J Clin Microbiol
1989;27:589±92.
18. Power UF, Plotnicky-Gilquin H, Huss T, et al. Induction of protective im-
munity in rodents by vaccination with a prokaryotically expressed recom-
binant fusion protein containing a respiratory syncytial virus G protein
fragment. Virology 1997;230:155±66.
19. Brandt C, Power UF, Plotnicky-Gilquin H, et al. Protective immunity against
respiratory syncytial virus in early life after murine maternal or neonatal
vaccination with the recombinant G fusion protein BBG2Na. J Infect Dis
1997;176:884±91.
20. Murby M, Samuelsson E, Nguyen TN, et al. Hydrophobicity engineering to
increase solubility and stability of a recombinant protein from respiratory
syncytial virus. Eur J Biochem 1995;230:38±44.
21. Taylor G, Stott EJ, Hughes M, Collins AP. Respiratory syncytial virus in-
fection in mice. Infect Immun 1984;43:649±55.
22. Barrios C, Brandt C, Berney M, Lambert PH, Siegrist CA. Partial correction
of the TH1/TH2 imbalance in neonatal murine responses to vaccine an-
tigens through selective adjuvant effects. Eur J Immunol 1996;26:2666±70.
23. Audibert FM, Lise LD. Adjuvants: current status, clinical perspectives and
future prospects. Immunol Today 1993;14:281±4.
24. Kovarik J, Siegrist CA. Immunity in early life. Immunol Today 1998;19:
150±2.
25. Brandenburg AH, Groen J, van Steensel-Moll HA, et al. Respiratory syn-
cytial virus speci®c serum antibodies in infants under six months of age:
limited serological response upon infection. J Med Virol 1997;52:97±104.
26. Barrios C, Brawand P, Berney M, Brandt C, Lambert PH, Siegrist CA.
Neonatal and early life immune responses to various forms of vaccine
antigens qualitatively differ from adult responses: predominance of a Th2-
biased pattern which persists after adult boosting. Eur J Immunol 1996;26:
1489±96.
27. Singh RR, Hahn BH, Sercarz EE. Neonatal peptide exposure can prime T
cells and upon subsequent immunization induce their immune deviation:
implications for antibody versus T cell±mediated autoimmunity. J Exp
Med 1996;183:1613±21.
28. Forsthuber T, Yip HC, Lehmann PV. Induction of TH1 and TH2 immunity
in neonatal mice. Science 1996;271:1728±30.
29. Warris ME, Tsou C, Erdman DD, Zaki SR, Anderson LH. Respiratory
syncytial virus infection in BALB/c mice previously immunized with for-
malin-inactivated virus induces enhanced pulmonary in¯ammatory re-
sponse with a predominant Th2-like cytokine pattern. J Virol 1996;70:
2852±60.
JID 1999;179 (June) Neonatal Immunity and Protection against RSV 1333
30. Stott EJ, Taylor G, Ball LA, et al. Immune and histopathological responses
in animals vaccinated with recombinant vaccinia viruses that express in-
dividual genes of human respiratory syncytial virus. J Virol 1987;61:
3855±61.
31. Alwan WH, Kozlowska WJ, Openshaw PJ. Distinct types of lung disease
caused by functional subsets of antiviral T cells. J Exp Med 1994;179:
81±9.
32. Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C. Gen-
eration of atypical pulmonary in¯ammatory responses in BALB/c mice
after immunization with the native attachment (G) glycoprotein of res-
piratory syncytial virus. J Virol 1996;70:7783±91.
33. Corvaia N, Tournier P, Nguyen TN, et al. Challenge of BALB/c mice with
respiratory syncytial virus does not enhance the Th2 pathway induced
after immunization with a recombinant G fusion protein, BBG2Na, in
aluminum hydroxide. J Infect Dis 1997;176:560±9.
34. Plotnicky-Gilquin H, Huss T, Aubry JP, et al. Absence of immunopathology
following respiratory syncytial virus (RSV) challence of BALB/c mice
immunized with BBG2Na, a recombinant RSV vaccine candidate. Virol
(in press).
35. Hemming VG, Prince GA, Groothuis JR, Siber GR. Hyperimmune globulins
in prevention and treatment of respiratory syncytial virus infections. Clin
Microbiol Rev 1995;8:22±33.
36. Bangham CR. Passively acquired antibodies to respiratory syncytial virus
impair the secondary cytotoxic T-cell response in the neonatal mouse.
Immunology 1986;59:37±41.
37. Prince GA, Horswood RL, Camargo E, Suf®n SC, Chanock RM. Parenteral
immunization with live respiratory syncytial virus is blocked in seropos-
itive cotton rats. Infect Immun 1982;37:1074±8.
38. Murphy BR, Olmsted RA, Collins PL, Chanock RM, Prince GA. Passive
transfer of respiratory syncytial virus (RSV) antiserum suppresses the
immune response to the RSV fusion (F) and large (G) glycoproteins ex-
pressed by recombinant vaccinia viruses. J Virol 1988;62:3907±10.
39. Murphy BR, Prince GA, Collins PL, Hildreth SW, Paradiso PR. Effect of
passive antibody on the immune response of cotton rats to puri®ed F and
G glycoproteins of respiratory syncytial virus (RSV). Vaccine 1991;9:
185±9.
40. Siegrist CA, Barrios C, Martinez X, et al. In¯uence of maternal antibodies
on vaccine responses: inhibition of antibody but not T cell responses allow
successful early prime-boost strategies in mice. Eur J Immunol 1998;28:
4138±48.
41. Englund JA, Anderson EL, Reed GF, et al. The effect of maternal antibody
on the serologic response and the incidence of adverse reactions after
primary immunization with acellular and whole-cell pertussis vaccines
combined with diphtheria and tetanus toxoids. Pediatrics 1995;96:580±4.
